Adaptimmune Short Term Investments vs Accounts Payable Analysis

ADAP Stock

USD 1.13 0.12 11.88%

Adaptimmune Therapeutics financial indicator trend analysis is way more than just evaluating Adaptimmune Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Adaptimmune Therapeutics is a good investment. Please check the relationship between Adaptimmune Therapeutics Short Term Investments and its Accounts Payable accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adaptimmune Therapeutics Plc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

Short Term Investments vs Accounts Payable

Short Term Investments vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Adaptimmune Therapeutics Short Term Investments account and Accounts Payable. At this time, the significance of the direction appears to have almost no relationship.

The correlation between Adaptimmune Therapeutics' Short Term Investments and Accounts Payable is 0.18. Overlapping area represents the amount of variation of Short Term Investments that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Adaptimmune Therapeutics Plc, assuming nothing else is changed. The correlation between historical values of Adaptimmune Therapeutics' Short Term Investments and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Term Investments of Adaptimmune Therapeutics Plc are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Short Term Investments i.e., Adaptimmune Therapeutics' Short Term Investments and Accounts Payable go up and down completely randomly.

Correlation Coefficient

0.18

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Short Term Investments

Short Term Investments is an item under the current assets section of Adaptimmune Therapeutics balance sheet. It contains any investments Adaptimmune Therapeutics Plc undertook that will expire in less than one year. These accounts contain financial instruments such as stocks or bonds that Adaptimmune Therapeutics can easily liquidate in the marketplace.

Accounts Payable

An accounting item on the balance sheet that represents Adaptimmune Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Adaptimmune Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most indicators from Adaptimmune Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Adaptimmune Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adaptimmune Therapeutics Plc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

As of 06/01/2024, Selling General Administrative is likely to drop to about 37.2 M. In addition to that, Tax Provision is likely to drop to about 832.7 K

	2021	2022	2023	2024 (projected)
Net Interest Income	1.1M	1.5M	6.0M	6.3M
Interest Income	1.1M	1.5M	6.0M	6.3M

Net Interest Income Interest Income

Adaptimmune Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Short Long Term Debt Total	Common Stock Shares Outstanding	Short Term Debt	Property Plant Equipment	Net Tangible Assets
Total Assets		0.31	0.61	0.77	0.63	-0.38	-0.6	0.6	0.63	0.66	0.39	0.96	0.15	0.83	0.59	0.7	0.79	0.63	0.47	0.99	0.77	0.2	-0.79	0.04	0.51	0.83
Other Current Liab	0.31		0.74	-0.04	0.5	0.19	-0.51	0.21	-0.08	0.51	-0.04	0.18	0.18	0.4	0.42	0.49	0.52	0.52	0.4	0.24	0.39	0.06	0.01	-0.08	0.41	0.0
Total Current Liabilities	0.61	0.74		0.17	0.7	-0.17	-0.65	0.66	0.38	0.73	0.2	0.47	0.36	0.68	0.61	0.58	0.7	0.74	0.61	0.54	0.66	0.2	-0.42	0.05	0.67	0.24
Total Stockholder Equity	0.77	-0.04	0.17		0.12	-0.25	-0.01	0.34	0.53	0.26	0.62	0.85	-0.31	0.38	-0.05	0.35	0.34	-0.01	-0.07	0.81	0.29	0.49	-0.78	0.22	-0.02	0.99
Property Plant And Equipment Net	0.63	0.5	0.7	0.12		-0.02	-0.96	0.67	0.18	0.93	0.18	0.42	0.58	0.94	0.81	0.79	0.89	0.86	0.92	0.52	0.94	-0.22	-0.47	-0.38	0.94	0.23
Net Debt	-0.38	0.19	-0.17	-0.25	-0.02		0.11	-0.11	-0.87	0.08	0.07	-0.46	-0.29	-0.22	-0.31	0.13	-0.06	-0.3	-0.13	-0.45	-0.26	-0.24	0.46	-0.71	-0.09	-0.27
Retained Earnings	-0.6	-0.51	-0.65	-0.01	-0.96	0.11		-0.54	-0.19	-0.84	0.04	-0.41	-0.67	-0.91	-0.92	-0.71	-0.89	-0.93	-0.93	-0.5	-0.93	0.36	0.33	0.38	-0.91	-0.14
Accounts Payable	0.6	0.21	0.66	0.34	0.67	-0.11	-0.54		0.31	0.75	0.46	0.46	0.21	0.67	0.44	0.63	0.66	0.52	0.55	0.52	0.63	0.11	-0.58	-0.05	0.57	0.41
Cash	0.63	-0.08	0.38	0.53	0.18	-0.87	-0.19	0.31		0.16	0.27	0.68	0.26	0.42	0.3	0.07	0.24	0.34	0.22	0.68	0.43	0.52	-0.75	0.65	0.25	0.56
Non Current Assets Total	0.66	0.51	0.73	0.26	0.93	0.08	-0.84	0.75	0.16		0.34	0.44	0.32	0.86	0.66	0.85	0.94	0.71	0.75	0.54	0.83	-0.14	-0.51	-0.38	0.81	0.34
Other Assets	0.39	-0.04	0.2	0.62	0.18	0.07	0.04	0.46	0.27	0.34		0.37	-0.21	0.28	-0.24	0.27	0.18	-0.15	0.05	0.37	0.2	0.54	-0.68	0.1	0.14	0.6
Cash And Short Term Investments	0.96	0.18	0.47	0.85	0.42	-0.46	-0.41	0.46	0.68	0.44	0.37		0.05	0.68	0.44	0.54	0.6	0.47	0.29	0.99	0.62	0.31	-0.78	0.18	0.31	0.89
Net Receivables	0.15	0.18	0.36	-0.31	0.58	-0.29	-0.67	0.21	0.26	0.32	-0.21	0.05		0.56	0.62	-0.01	0.35	0.64	0.85	0.11	0.67	-0.18	-0.12	-0.04	0.76	-0.16
Common Stock Total Equity	0.83	0.4	0.68	0.38	0.94	-0.22	-0.91	0.67	0.42	0.86	0.28	0.68	0.56		0.8	0.75	0.91	0.84	0.87	0.75	0.99	-0.07	-0.66	-0.22	0.88	0.5
Non Current Liabilities Total	0.59	0.42	0.61	-0.05	0.81	-0.31	-0.92	0.44	0.3	0.66	-0.24	0.44	0.62	0.8		0.64	0.79	0.98	0.8	0.52	0.82	-0.39	-0.23	-0.27	0.78	0.05
Other Current Assets	0.7	0.49	0.58	0.35	0.79	0.13	-0.71	0.63	0.07	0.85	0.27	0.54	-0.01	0.75	0.64		0.85	0.66	0.5	0.61	0.66	-0.17	-0.45	-0.44	0.57	0.38
Other Stockholder Equity	0.79	0.52	0.7	0.34	0.89	-0.06	-0.89	0.66	0.24	0.94	0.18	0.6	0.35	0.91	0.79	0.85		0.81	0.74	0.69	0.87	-0.21	-0.48	-0.35	0.76	0.43
Total Liab	0.63	0.52	0.74	-0.01	0.86	-0.3	-0.93	0.52	0.34	0.71	-0.15	0.47	0.64	0.84	0.98	0.66	0.81		0.84	0.56	0.86	-0.27	-0.3	-0.21	0.83	0.09
Property Plant And Equipment Gross	0.47	0.4	0.61	-0.07	0.92	-0.13	-0.93	0.55	0.22	0.75	0.05	0.29	0.85	0.87	0.8	0.5	0.74	0.84		0.38	0.92	-0.23	-0.36	-0.28	0.96	0.08
Total Current Assets	0.99	0.24	0.54	0.81	0.52	-0.45	-0.5	0.52	0.68	0.54	0.37	0.99	0.11	0.75	0.52	0.61	0.69	0.56	0.38		0.69	0.26	-0.78	0.12	0.4	0.86
Common Stock	0.77	0.39	0.66	0.29	0.94	-0.26	-0.93	0.63	0.43	0.83	0.2	0.62	0.67	0.99	0.82	0.66	0.87	0.86	0.92	0.69		-0.1	-0.61	-0.2	0.91	0.42
Short Long Term Debt Total	0.2	0.06	0.2	0.49	-0.22	-0.24	0.36	0.11	0.52	-0.14	0.54	0.31	-0.18	-0.07	-0.39	-0.17	-0.21	-0.27	-0.23	0.26	-0.1		-0.51	0.71	-0.12	0.46
Common Stock Shares Outstanding	-0.79	0.01	-0.42	-0.78	-0.47	0.46	0.33	-0.58	-0.75	-0.51	-0.68	-0.78	-0.12	-0.66	-0.23	-0.45	-0.48	-0.3	-0.36	-0.78	-0.61	-0.51		-0.28	-0.43	-0.81
Short Term Debt	0.04	-0.08	0.05	0.22	-0.38	-0.71	0.38	-0.05	0.65	-0.38	0.1	0.18	-0.04	-0.22	-0.27	-0.44	-0.35	-0.21	-0.28	0.12	-0.2	0.71	-0.28		-0.27	0.19
Property Plant Equipment	0.51	0.41	0.67	-0.02	0.94	-0.09	-0.91	0.57	0.25	0.81	0.14	0.31	0.76	0.88	0.78	0.57	0.76	0.83	0.96	0.4	0.91	-0.12	-0.43	-0.27		0.11
Net Tangible Assets	0.83	0.0	0.24	0.99	0.23	-0.27	-0.14	0.41	0.56	0.34	0.6	0.89	-0.16	0.5	0.05	0.38	0.43	0.09	0.08	0.86	0.42	0.46	-0.81	0.19	0.11

Click cells to compare fundamentals

Adaptimmune Therapeutics Account Relationship Matchups

Adaptimmune Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	181.5M	451.1M	469.5M	328.9M	282.6M	268.1M
Other Current Liab	23.4M	27.1M	29.9M	33.5M	30.3M	21.7M
Total Current Liabilities	34.3M	39.1M	62.5M	64.5M	72.8M	44.6M
Total Stockholder Equity	123.6M	341.2M	206.0M	81.9M	39.5M	37.5M
Property Plant And Equipment Net	51.9M	46.7M	51.4M	71.5M	71.7M	75.3M
Net Debt	(25.0M)	(33.2M)	(124.5M)	(85.0M)	(118.8M)	(112.8M)
Retained Earnings	(455.7M)	(585.8M)	(743.8M)	(909.3M)	(1.0B)	(972.0M)
Accounts Payable	6.4M	6.4M	8.1M	4.8M	8.1M	5.5M
Cash	50.4M	56.9M	149.9M	108.0M	144.0M	112.8M
Non Current Assets Total	61.1M	53.0M	54.1M	73.5M	75.1M	39.1M
Other Assets	7.0M	4.6M	1.7M	1.6M	1.8M	1.7M
Cash And Short Term Investments	89.5M	368.2M	369.6M	204.6M	146.9M	202.8M
Net Receivables	(1.5M)	139K	752K	7.4M	46.9M	49.3M
Common Stock Total Equity	939K	943K	1.3M	1.3M	1.5M	1.6M
Liabilities And Stockholders Equity	181.5M	451.1M	469.5M	328.9M	282.6M	268.1M
Non Current Liabilities Total	23.6M	70.8M	201.0M	182.5M	170.3M	178.8M
Other Current Assets	30.9M	29.8M	45.1M	43.3M	13.7M	19.3M
Other Stockholder Equity	585.6M	935.7M	959.6M	990.7M	1.1B	535.2M
Total Liab	57.9M	109.9M	263.6M	247.0M	243.1M	255.3M
Property Plant And Equipment Gross	51.9M	46.7M	51.4M	71.5M	130.9M	137.5M
Total Current Assets	120.5M	398.2M	415.5M	255.4M	207.6M	229.0M
Accumulated Other Comprehensive Income	(7.3M)	(10.0M)	(11.1M)	(875K)	(3.7M)	(3.6M)
Common Stock	943K	1.3M	1.3M	1.4M	1.9M	2.0M
Short Long Term Debt Total	25.5M	23.7M	25.5M	23.1M	25.2M	38.5M
Common Stock Shares Outstanding	105.0M	142.5M	155.8M	161.2M	201.1M	129.5M
Property Plant Equipment	31.1M	27.8M	30.5M	71.5M	82.3M	86.4M
Net Tangible Assets	121.4M	339.5M	205.0M	81.4M	93.7M	89.0M
Non Currrent Assets Other	7.0M	4.6M	1.7M	1.6M	3.0M	3.6M
Short Term Investments	39.1M	311.3M	219.6M	96.6M	2.9M	2.8M
Other Liab	598K	49.9M	177.9M	162.2M	186.5M	195.8M
Inventory	1.5M	2.1M	746K	1.3M	1.3M	1.4M
Intangible Assets	2.2M	1.7M	1M	442K	330K	313.5K
Capital Surpluse	574.2M	585.6M	935.7M	959.6M	1.1B	657.5M
Retained Earnings Total Equity	(318.5M)	(455.7M)	(585.8M)	(743.8M)	(669.5M)	(636.0M)
Non Current Liabilities Other	23.6M	70.8M	201.0M	1.3M	1.4M	1.3M
Net Invested Capital	123.6M	341.2M	206.0M	81.9M	39.5M	37.5M
Net Working Capital	86.1M	359.1M	352.9M	190.9M	134.8M	233.6M
Capital Stock	943K	1.3M	1.3M	1.4M	1.9M	1.4M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Adaptimmune Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Adaptimmune Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Adaptimmune Therapeutics Plc Stock. Highlighted below are key reports to facilitate an investment decision about Adaptimmune Therapeutics Plc Stock:

How To Invest In Adaptimmune

Details

Is Adaptimmune Stock a good investment?

Details

What is Adaptimmune Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adaptimmune Therapeutics Plc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

Note that the Adaptimmune Therapeutics information on this page should be used as a complementary analysis to other Adaptimmune Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Complementary Tools for Adaptimmune Stock analysis

When running Adaptimmune Therapeutics' price analysis, check to measure Adaptimmune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptimmune Therapeutics is operating at the current time. Most of Adaptimmune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Adaptimmune Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptimmune Therapeutics' price. Additionally, you may evaluate how the addition of Adaptimmune Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
	Fundamental Analysis View fundamental data based on most recent published financial statements
	Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios.
	Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
	Risk-Return Analysis View associations between returns expected from investment and the risk you assume
	Performance Analysis Check effects of mean-variance optimization against your current asset allocation
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules
	ETFs Find actively traded Exchange Traded Funds (ETF) from around the world
	Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios
	Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities
	My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like

Is Adaptimmune Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adaptimmune Therapeutics. If investors know Adaptimmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adaptimmune Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.73)

Revenue Per Share

0.3

Quarterly Revenue Growth

(0.98)

Return On Assets

(0.28)

Return On Equity

(1.88)

The market value of Adaptimmune Therapeutics is measured differently than its book value, which is the value of Adaptimmune that is recorded on the company's balance sheet. Investors also form their own opinion of Adaptimmune Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Adaptimmune Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adaptimmune Therapeutics' market value can be influenced by many factors that don't directly affect Adaptimmune Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Adaptimmune Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adaptimmune Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adaptimmune Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Adaptimmune Short Term Investments vs Accounts Payable Analysis

Short Term Investments vs Accounts Payable

Short Term Investments vs Accounts Payable Correlation Analysis

Correlation Coefficient

Short Term Investments

Accounts Payable

Adaptimmune Therapeutics fundamental ratios Correlations

Adaptimmune Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Adaptimmune Therapeutics fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Adaptimmune Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 0.99	Total Assets
Net Tangible Assets	+ 0.99	Total Stockholder Equity
Total Current Assets	+ 0.99	Cash And Short Term Investments
Common Stock	+ 0.99	Common Stock Total Equity
Total Liab	+ 0.98	Non Current Liabilities Total
Cash And Short Term Investments	+ 0.96	Total Assets

Retained Earnings	- 0.96	Property Plant And Equipment Net
Common Stock	- 0.93	Retained Earnings
Property Plant And Equipment Gross	- 0.93	Retained Earnings
Total Liab	- 0.93	Retained Earnings
Non Current Liabilities Total	- 0.92	Retained Earnings
Property Plant Equipment	- 0.91	Retained Earnings